Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal

Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meyer,Lital, Simian,Daniela, Lubascher,Jaime, Acuña,Raúl, Figueroa,Carolina, Silva,Guillermo, Brahm,Javier, Quera,Rodrigo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2015
Materias:	Crohn Disease Colitis ulcerative Drug-related side effects and adverse reactions Inflammatory Bowel Disease
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872015000100001
record_format	dspace
spelling	oai:scielo:S0034-988720150001000012015-08-11Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinalMeyer,LitalSimian,DanielaLubascher,JaimeAcuña,RaúlFigueroa,CarolinaSilva,GuillermoBrahm,JavierQuera,Rodrigo Crohn Disease Colitis ulcerative Drug-related side effects and adverse reactions Inflammatory Bowel Disease Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.1 20152015-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001es10.4067/S0034-98872015000100001
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Crohn Disease Colitis ulcerative Drug-related side effects and adverse reactions Inflammatory Bowel Disease
spellingShingle	Crohn Disease Colitis ulcerative Drug-related side effects and adverse reactions Inflammatory Bowel Disease Meyer,Lital Simian,Daniela Lubascher,Jaime Acuña,Raúl Figueroa,Carolina Silva,Guillermo Brahm,Javier Quera,Rodrigo Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
description	Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.
author	Meyer,Lital Simian,Daniela Lubascher,Jaime Acuña,Raúl Figueroa,Carolina Silva,Guillermo Brahm,Javier Quera,Rodrigo
author_facet	Meyer,Lital Simian,Daniela Lubascher,Jaime Acuña,Raúl Figueroa,Carolina Silva,Guillermo Brahm,Javier Quera,Rodrigo
author_sort	Meyer,Lital
title	Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_short	Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_full	Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_fullStr	Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_full_unstemmed	Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_sort	eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
publisher	Sociedad Médica de Santiago
publishDate	2015
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001
work_keys_str_mv	AT meyerlital eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT simiandaniela eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT lubascherjaime eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT acunaraul eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT figueroacarolina eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT silvaguillermo eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT brahmjavier eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal AT querarodrigo eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
_version_	1718436797111861248

Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal

Ejemplares similares